LECT-1 and BMP-2 Biomolecule Delivery for Bone and Cartilage Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for regenerating bone and cartilage, such as autologous bone grafting, are limited by the scarcity of donor tissue, high cost, and donor site morbidity, and are ineffective for complex fractures or defects where autologous bone transplantation is not possible.
Innovation Solution
Administering leukocyte cell-derived chemotaxin-1 (LECT-1) and bone morphogenetic protein-2 (BMP-2) biomolecules, optionally within biocompatible scaffolds, to activate stem cells and induce bone or cartilage formation in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous bone grafting is used to repair complex fractures or critical-size defects, then bone regeneration is achieved, but donor site morbidity and surgical complexity increase
Solution Approach 1:
The patent uses LECT-1 and BMP-2 as intermediary biomolecules that mediate the bone regeneration process. These proteins act as signaling molecules that stimulate endogenous stem cells to differentiate into osteoblasts, eliminating the need to harvest bone from the donor site while still achieving effective bone repair through biological mediation rather than direct tissue transplantation
Solution Approach 2:
The invention enables the patient's own body to regenerate bone tissue by activating and directing endogenous mesenchymal stem cells through the administration of LECT-1 and BMP-2. This self-service approach allows the body to produce the needed bone tissue autonomously, eliminating donor site morbidity while maintaining regeneration effectiveness
2Reliability
If autologous bone grafting is performed to regenerate bone tissue, then bone repair is achieved, but surgical procedure complexity and cost increase
Solution Approach 1:
The patent extracts and isolates the essential regenerative signaling components (LECT-1 and BMP-2 proteins) from the complex autologous bone grafting procedure. By administering these specific biomolecules directly to the defect site, the invention eliminates the need for complex surgical procedures involving bone harvesting, graft preparation, and implantation, while maintaining bone repair effectiveness through targeted molecular therapy
3Quantity of substance
If more autologous bone is collected to repair extensive bone damage, then bone regeneration capacity increases, but donor site morbidity and surgical time increase
Solution Approach 1:
The invention changes the fundamental parameter of bone regeneration from a mechanical quantity-based approach (amount of bone graft material) to a biological signaling-based approach (concentration and activity of LECT-1 and BMP-2 proteins). This parameter change allows extensive bone damage to be repaired by stimulating endogenous cell proliferation and differentiation, eliminating the need for prolonged surgical bone collection while achieving sufficient regeneration capacity through biological amplification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Facilitates effective regeneration of bone and cartilage by promoting differentiation of progenitor cells into chondroblasts and osteoblasts, providing a viable alternative to autologous bone grafting with reduced donor site morbidity and cost.
Implementation Method 1
administering a leukocyte cell-derived chemotaxin-1 (LECT-1) biomolecule and a bone morphogenetic protein-2 (BMP-2) biomolecule into an in vivo target site, whereby bone is generated in the in vivo target site
Implementation Method 2
activate stem cells and induce bone or cartilage formation in vivo
Data Source
AI summary
The present invention provides methods of generating bone and cartilage in vivo. The methods include delivering leukocyte cell-derived chemotaxin-1 (LECT-1) biomolecules and bone morphogenetic protein-2 (BMP-2) biomolecules into an in vivo target site, preferably by using biocompatible scaffolds containing the biomolecules.